Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Brain, heart, digestive tract symptoms common in aHUS: Study

Disease manifestations that affect the brain, such as seizures, are relatively common with atypical hemolytic uremic syndrome (aHUS), as are digestive symptoms and heart-related problems, a study finds. The study, “Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis,” was published in Pediatric…

Soliris resolves digestive disease in girl with aHUS: Report

A girl in China had atypical hemolytic uremic syndrome (aHUS) and accompanying protein-losing enteropathy (PLE), a condition in which there is an excessive loss of proteins through the gastrointestinal tract. Treatment with Soliris (eculizumab) resolved both her aHUS-related kidney disease and PLE, according to a report. “Our case…

Boy develops aHUS while receiving chemotherapy: Case report

A toddler developed atypical hemolytic uremic syndrome (aHUS) while receiving chemotherapy to treat cancer, according to a case report. It’s easy for aHUS in cancer patients undergoing chemotherapy to be missed, since its symptoms are often mistakenly assumed to be complications caused by cancer or treatment, said the…

aHUS triggered by pancreatitis in man, 49: Case report

The case of a 49-year-old man with atypical hemolytic uremic syndrome (aHUS) that manifested after he developed pancreatitis was described in a recent report. Genetic testing showed the man had a mutation in the MCP gene, a known risk factor for aHUS. The fact that he hadn’t had any…

Soliris found effective for aHUS tied to MCPggaac haplotype: Study

Complement-blocking medications like Soliris (eculizumab) can be effective for controlling atypical hemolytic uremic syndrome (aHUS) in patients carrying a genetic variant called the MCPggaac haplotype, a new study reports. Researchers in Southeastern Europe reviewed the cases of 14 children in the region with aHUS to determine the best…